蒋晟 - 中国药科大学

个人简介

蒋晟，教授，博士生导师。2003年毕业于中国科学院上海有机化学研究所，并获得有机化学博士学位。2003年—2007年在美国卫生部国立癌症研究所（NCI/NIH）从事博士后研究。2008年归国后,任中国科学院广州生物医药与健康研究院研究员、博士生导师, 课题组组长。现为中国药科大学药物化学系博士生导师, 课题组组长。兼任美国化学会会员，美国多肽学会会员，中国化学会会员，中国药学会高级会员。被聘为多个国际期刊如J. Med Chem.、Bioorg. Med. Chem. Lett. 、Bioorg. Med. Chem.、Eur. J. Med Chem. 、 J. Org. Chem、Organic Letters 等杂志特约审稿人，国家自然科学基金项目等项目评审专家。近年来，共发表了68篇SCI论文，包括：国际核心杂志Angew. Chem. Int. Ed., Organic Letters, Journal of Medicinal Chemistry 及Journal of The American Chemical Society 等发表的一系列具有创新性的文章。其中，“Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target”在国际刊物ACS Chemical Biology 上发表后，引起了国际同行的浓厚兴趣，被评选为该刊物2008 年第一季度最热门文章之一（most-accessed article of the 1st quarter of 2008）。学习经历 1993，9-1997，7：中国药科大学，药物化学，学士 1997，9-2000，7：中国药科大学，药物化学，硕士 2000，9-2003，7：中科院上海有机化学研究所，有机化学，博士工作经历 2003，11-2007，11：美国国家健康研究院（NIH）癌症研究所（NCI）；药物化学，博士后 2007，12-2016,12：中科院广州生物与健康研究院，药物化学，博士生导师, 课题组组长。 2017,1-现在：中国药科大学，药物化学，博士生导师, 课题组组长。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

J. Bai, , C. Liao, D. Qin, Y. Liu, X. Qing, J. Chen, Z. Li, Z. Tu, S. Jiang.* Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising In Vitro and in Vivo Antitumor Activities. J. Med. Chem. 2016, 59, 5766-5779. 2.N. Ma, Y. Luo, Y. Wang, C. Liao, W.-C. Ye*, S. Jiang*. Selective histone deacetylase inhibitors with anticancer activity. Curr. Top. Med. Chem. 2016, 16, 415-426. 3.Y. Jin, Y. Yao, L. Chen, X. Zhu, B. Jin, Y. Shen, J. Li, X. Du, Y. Lu, S. Jiang*, J. Pan*. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with imatinib. Theranostics. 2016, 6, 1947-1962. 4.Y. Yao, Z. Tu, C. Liao, Z. Wang, S. Li, H. Yao, Z. Li, S. Jiang*. Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro Selectivity for Cancers Cells and in Vivo Antitumor Activities. J. Med. Chem. 2015, 58, 7672-7680. 5.Y. Yao, Z. Li, Y. Qiu, J. Su, S. Jiang*. Unprecedented reactions: from epichlorohydrin to epoxyglycidyl substituted divinyl ether and its conversion into epoxyglycidyl propargyl ether. ScientificReports. 2015,5, srep14231. 6.N. Ma, Y. Wang, B. Zhao, W.-C. Ye*, S. Jiang*. The application of click chemistry in the synthesis of agents with anticancer activity. Drug Design, Development and Therapy. 2015, 50, 1585-1599. 7.J. Zhang, H. Zhou, S. Jiang, J. Jin, W. Li, W. Wang, S. Su. AA092, an annonaceous acetogenin mimetic, attenuates angiogenesis in a mouse model of inflammation-induced corneal neovascularization. International Immunopharmacology. 2015, 28, 997-1002. 8.Y. Zhou, G. Hou, S. He, Z. Xiao, H. Xu, Y. Qiu, S. Jiang, H. Zheng, Z. Li. Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells. CNS Neuroscience & Therapeutics. 2015, 21, 558-567. 9.N. Ma, Y. Yao, B.-X. Zhao, Y. Wang, W.-C. Ye*, S. Jiang*. Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun. 2014, 50, 9284-9287. 10.X. Zhu, L. Chen, S. Jiang, C. Chen, Y. Yao, D. Chen, H. Xue, J. Pan *. PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biology & Therapy. 2014, 15, 119-127. 11.J. Su, Y. Qiu, S. Jiang*, D. Zhang*. New Ligands for Copper-Catalyzed C[n.63743]N Coupling Reactions at Gentle Temperature. Chinese Journal of Chemistry. 2014, 32(8), 685-688. 12.J. Su, Y. Qiu, K. Ma, Y. Yao, Z. Wang, X. Li, D. Zhang, Z. Tu, S. Jiang*. Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain. Tetrahedron.2014, 70, 7763-7769. 13.H. Zhou, S. Jiang, J. Chen, X. Ren, J. Jin, S. B. Su*. Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization. European Journal of Pharmacology.2014, 740, 619-626. 14.H. Zhou, S. Jiang, J. Chen, S. B. Su*. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Can. J. Physiol. Pharmacol.2014, 92, 879-885. 15.Y. Liu, Y. Liu, Z. Liu, G. Zhou, Z.-J. Yao*, S. Jiang*. Identification of novel bivalent mimetics of annonaceous acetogenins via a scaffold-hopping strategy. Bioorg. Med. Chem. Lett. 2014, 24, 1650-1653. 16.Y. Liu, Q. Xiao, Y. Liu, Z. Li, Y. Qiu, G.-B. Zhou, Z.-J. Yao, S. Jiang*. Biological evaluation of new mimetics of annonaceous acetogenins: alteration of right scaffold by click linkage with aromatic functionalities. Eur. J. Med. Chem. 2014, 78, 248-258. 17.Y. Yao, C. Liao, Z. Li, Z. Wang, Q. Sun, C. Liu, Z. Tu*, S. Jiang*. Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted-Pyrazole Derivatives as New Class I and IIb Histone Deacetylase Inhibitors. Eur. J. Med. Chem. 2014, 86, 639-652. 18.Y. Zhao, X. Fang, Y. Wang, J. Zhang, S. Jiang, Z. Liu, Z. Ma, L. Xu, E. Li, K. Zhang. Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor. Current Pharmaceutical Design. 2014, 20, 1866-1873. 19.D. Zou, Y. Qiu, Z. Tu, C. Liao, J. Luo, Q. Meng, R. Yao, Z. Li, S. Jiang*.. Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. Science China: Chemistry. 2014, 57, 823-832. 20.Q. Meng, F. Li, S. Jiang, Z. Li*. Novel 64Cu-labeled CUDC-101 for in vivo PET Imaging of histone deacetylases. ACS Medicinal Chemistry Letters. 2013, 4, 858-862.